Abstract
This paper presents the architecture of the electronic detection and data processing (analysis) part, of a Lab-on- Chip (LoC) device. The data processing part focuses on the analysis of signals captured from the sensors used to detect possible mutations in the sample under consideration. The LoC consists of a micro-fluidics part for the sample preparation and hybridization, a micro-system part including the sensors for the hybridization electronic detection and finally a processing part for the data analysis and an interface for results presentation. The use of such LoCs aims at identifying the appropriate cluster of patients for a pharmacogenomic medicine based on the gene analysis results and at optimizing the effectiveness of the drug or determining whether the affected patient belongs to a group of patients who would suffer severe side effects.
Keywords: Lab-on-chip, embedded system, multi-core SoC, microarray, sensor signal processing, pharmacogenomics
Micro and Nanosystems
Title: Lab-on-Chip for Pharmacogenomics: An Embedded System Organization
Volume: 1 Issue: 1
Author(s): George Kornaros, Athanasios Demiris and Spyros Blionas
Affiliation:
Keywords: Lab-on-chip, embedded system, multi-core SoC, microarray, sensor signal processing, pharmacogenomics
Abstract: This paper presents the architecture of the electronic detection and data processing (analysis) part, of a Lab-on- Chip (LoC) device. The data processing part focuses on the analysis of signals captured from the sensors used to detect possible mutations in the sample under consideration. The LoC consists of a micro-fluidics part for the sample preparation and hybridization, a micro-system part including the sensors for the hybridization electronic detection and finally a processing part for the data analysis and an interface for results presentation. The use of such LoCs aims at identifying the appropriate cluster of patients for a pharmacogenomic medicine based on the gene analysis results and at optimizing the effectiveness of the drug or determining whether the affected patient belongs to a group of patients who would suffer severe side effects.
Export Options
About this article
Cite this article as:
Kornaros George, Demiris Athanasios and Blionas Spyros, Lab-on-Chip for Pharmacogenomics: An Embedded System Organization, Micro and Nanosystems 2009; 1 (1) . https://dx.doi.org/10.2174/1876402910901010030
DOI https://dx.doi.org/10.2174/1876402910901010030 |
Print ISSN 1876-4029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-4037 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase
Central Nervous System Agents in Medicinal Chemistry Towards the Treatment of Polyglutamine Diseases: The Modulatory Role of Protein Context
Current Medicinal Chemistry Editorial: The Need for an Effective Hangover Cure
Current Drug Abuse Reviews ERRATUM
Current Alzheimer Research Neuroactive Steroids as Endogenous Modulators of Anxiety
Current Pharmaceutical Design Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1
Current Neurovascular Research Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews alpha Conotoxins Nicotinic Acetylcholine Receptor Antagonists as Pharmacological Tools and Potential Drug Leads
Current Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Modulating the Amyloidogenesis of α-Synuclein
Current Neuropharmacology Nano Era of Dentistry-An Update
Current Drug Delivery The Case for Development of 11-Aza-artemisinins for Malaria
Current Medicinal Chemistry Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Reprogramming of B Cells into Regulatory Cells with Engineered Fusokines
Infectious Disorders - Drug Targets Dedication:
CNS & Neurological Disorders - Drug Targets Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction
Current Alzheimer Research Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design